Online pharmacy Alto, which offers same-day deliveries and medication management apps, raises $50M Series C from Greenoaks Capital and others
Context & Ripple Effects
Alto's $50M Series C is a follow-on bet by the same lead: Greenoaks Capital backed the company's rebrand from ScriptDash and $23M Series B in mid-2017 for nationwide expansion, and is now doubling down eighteen months later on the same-day delivery and medication-management model.
The raise lands in a fast-heating category — NYC rival Capsule pulled in an identical $50M just four months earlier to expand nationally within 12 to 18 months, making delivery speed and pharmacist access the visible battleground.
First-order effects
- Alto gets fresh capital to push its same-day delivery and medication-management app beyond its current footprint, directly against Capsule's announced national rollout window.
Second-order effects
- Capsule and other delivery-first pharmacies face pressure to keep raising at a matching cadence, while specialty-drug players like Phil — which raised a $25M Series B connecting doctors, pharmacies and insurers — compete for the same doctor-and-insurer integration channels.
Third-order effects
- The pattern holds into mega-rounds: Alto later draws a reported ~$250M SoftBank-led round at over $1B valuation and Ro raises $500M, pointing toward digital pharmacies consolidating into heavily capitalized challengers to CVS and Walgreens rather than staying niche startups.
The trend: Digital pharmacies are scaling from regional delivery services into billion-dollar, venture-mega-round-backed platforms aimed at displacing retail chain pharmacies.